Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton May 30, 2023 10:17pm

201 Views

Post# 35471509

RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

The 66% CR represents CR at any time which is the primary objective. The 60% CR is the CR at 90 days. On the swimmer's plot there are 3 patients who were NR at 90 days but went on to achieve a CR at a later time period.

TriumphSpitSix wrote: Nevermind I guess. The chart in the news release is different than the chart in the MDA with the 60% vs 66% figure being different based on whether the patient was "evaluated by a PI" or not.

They still haven't found a simple and cogent way to present all this information...

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price